After decades of slow progress in understanding and developing effective treatments for Alzheimer’s disease, scientists are ...
(WHTM) — A global campaign is marking Brain Awareness Week through Sunday, and Penn State professors are explaining some of ...
In the brain, Alzheimer’s is characterized by two proteins, amyloid beta and tau, that become dysfunctional, forming plaques ...
What happens when a promising therapy falls short? Medscape spoke with Jeffrey Cummings, MD, who led the EVOKE trials of the GLP-1 semaglutide for AD, about what the results mean — and what comes next ...
6don MSNOpinion
I was a doctor caring for Alzheimer’s patients. At 57, I became one. Here’s what’s next
Internal medicine doctor diagnosed with Alzheimer's at 57 shares how monoclonal antibody treatment restored his cognitive ...
GLP-1 receptor agonist indications continue to expand beyond glycaemic and weight control, with benefits now shown in chronic kidney disease in type 2 diabetes, obesity-related heart failure, knee ...
MedPage Today on MSN
An Alzheimer's revolution is coming, experts say
Research roundtable highlights early detection, biomarkers, interventions ...
Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the ...
Source: Garrondo, Public domain, via Wikimedia Commons Have you ever heard someone claim that cognitive decline or even dementia is inevitable as we age, and wondered if that doom-and-gloom statement ...
Research from UC Santa Cruz indicates that the P3 peptide—an alternative cleavage product of the amyloid precursor protein—may play a role in Alzheimer’s disease.
New findings suggest that targeting inflammation in Alzheimer’s may matter as much as targeting protein buildup.
Many Black and Latino families are navigating Alzheimer’s without access to the information, resources, and community support ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results